Paroxetine
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Paroxetine: From SSRI Antidepressant to Ohdo Syndrome and Variants
One-Sentence Summary
Paroxetine (DB00715) is a widely used selective serotonin reuptake inhibitor (SSRI); the evidence pack does not include a specific original-indication text or DrugBank-sourced original MOA. The TxGNN model predicts a possible link to Ohdo syndrome and variants, an ultra-rare chromatin-modification genetic disorder, but this prediction is supported by zero clinical trials and zero publications, and the model's own rationale flags it as a likely false positive.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (no original_indications or license text available) |
| Predicted New Indication | Ohdo syndrome and variants |
| TxGNN Prediction Score | 99.11% |
| Evidence Level | L5 |
| New Zealand Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (data gap DG002, High severity). No original_indications were provided in the evidence pack either, so the drug's established clinical use cannot be characterized from this data source alone.
Based on the repurposing rationale supplied with this candidate, Ohdo syndrome (including the SBBYS/Say-Barber-Biesecker-Young-Simpson variant) is a monogenic developmental disorder caused by dysfunction of chromatin-modifying genes such as KAT6A/KAT6B (histone acetyltransferases). Paroxetine's known pharmacological target is the serotonin transporter (SERT), which has no established mechanistic connection to KAT6A/KAT6B chromatin regulation.
Given the combination of missing original-MOA data, an unmarketed status in New Zealand, and the absence of any supporting trials or literature, the evidence pack itself assesses this TxGNN score as most likely a model false positive arising from a sparsely connected region of the knowledge graph, rather than a biologically grounded signal.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
New Zealand Market Information
Paroxetine is currently not marketed in New Zealand under this evidence pack, and no product authorizations are on file (total licenses: 0).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but evidence level is L5 (model prediction only) — no clinical trials, no literature, no established mechanistic link between SERT inhibition and the KAT6A/KAT6B pathway underlying Ohdo syndrome. The evidence pack's own rationale flags this as a probable false positive.
To proceed, the following is needed:
- Regulatory/package-insert warnings and contraindications (DG001, Blocking — required before any S1 safety screening)
- Confirmed mechanism of action from DrugBank or equivalent source (DG002)
- Any preclinical or mechanistic evidence connecting serotonergic modulation to KAT6A/KAT6B-related chromatin disorders
- Re-evaluation once literature/clinical-trial evidence emerges, or reprioritization toward higher-confidence candidates in this drug's pipeline
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.